April 23, 2020 10:40 AM EDTUpdated 10:53 AM

It's not developing drugs that bind to RNA, or morphing RNA into a therapeutic — this Cambridge startup has scored $63M to work on RNA-modifying proteins

First came the concept of epigenetics, the study of chemical modifications made to the blueprint of life — DNA — to switch genes on or off. Then …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

It's not de­vel­op­ing drugs that bind to RNA, or mor­ph­ing RNA in­to a ther­a­peu­tic — this Cam­bridge start­up has scored $63M to work on RNA-mod­i­fy­ing pro­teins